
Join to View Full Profile
1190 5th AveNew York, NY 10029
Phone+1 212-241-6756
Fax+1 212-423-0522
Dr. Brody is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
- Yale-New Haven Medical CenterResidency, Internal Medicine, 2000 - 2003
- Stony Brook University Health Sciences Center School of MedicineClass of 2000
Certifications & Licensure
- CA State Medical License 2003 - Present
- NY State Medical License 2012 - 2027
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma Start of enrollment: 2011 Feb 01
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers Start of enrollment: 2011 Oct 01
- In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy Start of enrollment: 2014 Jan 03
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsA patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.Danilo Fiore, Luca Vincenzo Cappelli, Liu Zhaoqi, Nikita Kotlov, Maria Sorokina
Cell Reports. Medicine. 2025-04-15 - 1 citationsEpcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.Joshua D Brody, Judit Jørgensen, David Belada, Régis Costello, Marek Trněný
Blood. 2025-04-10 - Enhancing antitumor immunity through chemotherapeutic-derived lipid nanoparticle-induced immunogenic cell death and CD40L/Flt3L mRNA-mediated dendritic cell activation.Xucheng Hou, Chang Wang, Yichen Zhong, Leiming Wang, Diana D Kang
Journal of Controlled Release. 2025-04-02
Press Mentions
- Chemotherapy and Immunotherapy Combo Shows Promise for Aggressive LymphomaJanuary 23rd, 2025
- High-Dose Chemo, ASCT Improves Survival in Primary CNS LymphomaDecember 14th, 2022
- Novel Vaccine Approach Halts Disease After 23 Years of Breast CancerDecember 10th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: